Description
DE-OBLIGATED EXCESS FUNDS-BLOOD BANK REAGENTS
Base award description: BLOOD BANK REAGENTS
Modification chain · 6 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-10-01+$23,808= $23,808
- Mod P000012021-07-01+$17,547= $41,354
- Mod P000022021-07-01+$2,000= $43,354
- Mod P000042022-02-16+$342= $43,696
- Mod P000052022-05-16-$10,553= $33,143
- Mod P000072022-05-18-$5,920= $27,223
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-10-01 | +$23,808 | $23,808 | BLOOD BANK REAGENTS |
| Mod P00001· EXERCISE AN OPTION | 2021-07-01 | +$17,547 | $41,354 | BLOOD BANK REAGENTS |
| Mod P00002· FUNDING ONLY ACTION | 2021-07-01 | +$2,000 | $43,354 | BLOOD BANK REAGENTS |
| Mod P00004· FUNDING ONLY ACTION | 2022-02-16 | +$342 | $43,696 | BLOOD BANK REAGENTS |
| Mod P00005· FUNDING ONLY ACTION | 2022-05-16 | −$10,553 | $33,143 | DE-OBLIGATED EXCESS FUNDS-BLOOD BANK REAGENTS |
| Mod P00007· FUNDING ONLY ACTION | 2022-05-18 | −$5,920 | $27,223 | DE-OBLIGATED EXCESS FUNDS-BLOOD BANK REAGENTS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V6KNKL6BDHL7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25526N0306 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $40,949 | FY2026 |
| 36C25926N0280 | NETWORK CONTRACT OFFICE 19 (36C259) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $64,078 | FY2026 |
| 36C25726N0176 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $7,634 | FY2026 |
| 36C25726N0224 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $16,514 | FY2026 |
| 36C25626N0214 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $23,127 | FY2026 |
| 36C25026N0043 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $21,884 | FY2026 |
Other recipients under 6550 from NETWORK CONTRACT OFFICE 19 (36C259) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25926N0457 | BECTON, DICKINSON AND COMPANY | NETWORK CONTRACT OFFICE 19 (36C259) | $147,256 | FY2026 |
| 36C25926N0353 | QIAGEN, LLC | NETWORK CONTRACT OFFICE 19 (36C259) | $88,310 | FY2026 |
| 36C25926N0292 | FISHER SCIENTIFIC COMPANY L.L.C. | NETWORK CONTRACT OFFICE 19 (36C259) | $165,000 | FY2026 |
| 36C25926N0316 | POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC | NETWORK CONTRACT OFFICE 19 (36C259) | $50,343 | FY2026 |
| 36C25926N0324 | BIOFIRE DIAGNOSTICS LLC | NETWORK CONTRACT OFFICE 19 (36C259) | $186,386 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25921F0018_3600_V797P2050D_3600 · retrieved 2026-09-26.